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Chronic hepatitis in United
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W L Irving, KR Neal, J C E Underwood,
P N Simmonds, V James, on behalf ofTrent
Regional Hepatitis C Virus Study Group
Routine screening for antibodies to hepatitis C virus in
blood donations was introduced in Britain in 1991. It
showed that 1 in 2000 donors was positive for anti-
bodies. The natural course and importance of hepatitis
C virus infection in apparently healthy people are
unclear. We assessed the value of clinical and labora-
tory data in predicting the need for liver biopsy in
blood donors with antibodies to hepatitis C virus.
Patients, methods, and results
Blood donors in the Trent region are screened for
antibodies to hepatitis C virus by second generation
enzyme linked immunosorbent assay, and results are
confirmed by a four antigen recombinant immunoblot
assay. Donors with positive results are interviewed and
referred to a consultant for further management. We
studied all 52 donors who had had a liver biopsy by
1 May 1993 (30 men, 22 women; aged 21-57 (mean 35)
years).
We collected data on risk factors for hepatitis C virus
infection, duration of infection (assuming that infection
was acquired on the first exposure to a risk factor),
and alcohol intake. Alanine aminotransferase con-
centrations (three measurements), GOR antibodies,'
hepatitis C virus RNA,' and hepatitis C virus serotype3
were measured. Biopsy specimens were scored blind
by the Knodell and Sheffield4 schemes; the Sheffield
scheme includes assessment of histological features
characteristic of hepatitis C. We used the statistical
package spss-pc to analyse data with Spearman rank
correlation, Mann-Whitney, and logistic regression
analyses. Predictive values for severe liver disease
(chronic active hepatitis or cirrhosis) were calculated
by using the standard definition and 95% confidence
intervals by the program Confidence Interval Analysis.
The histological diagnoses were cirrhosis (four
patients), chronic active hepatitis (13), chronic
persistent hepatitis (32), fatty change (one), and
normal (two). Hepatitis C virus RNA was detected in
sera from 51 donors. The biopsy specimen from the
donor without viral RNA was normal. Hepatitis C
virus RNA was assayed twice in 31 donors: 28 had
positive results in both samples, one had negative
results in both, and two had a positive result in the first
sample but a negative second result. The biopsy
specimens from the donors with discordant results
were reported as normal in one and chronic persistent
hepatitis with features of al antitrypsin deficiency in
the other. A negative test result was significantly associ-
ated with lower severity scores for biopsy specimens
(Knodell score P=0-006; Sheffield score P=0 005).
Peak alanine aminotransferase concentration was
correlated with both severity scores (Knodell score
r8=0 59, P<0-001; Sheffield score r,=0 66, p<0-001,
figure). The predictive value for chronic active hepatitis
or cirrhosis was 0-42 (13/31 donors, 95% confidence
interval 0-25 to 0-61) for an alanine aminotransferase
concentration above 60 IU/l and 0 47 (9/19, 0-24 to
07 1) for a concentration above 100 IU/l. The predictive
value of an alanine aminotransferase concentration
under 60 IU/l for chronic persistent hepatitis, fatty
change, or a normal biopsy result was 0-81 (17/21, 0-58
to 0 95).
Liver damage was more severe in men than women
(median Knodell score 4 v 2, P= 0 03; Sheffield score 5
v 3, P=0.02). Logistic regression models found no
other significant predictor for histological change.
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Comment
Fifty of 52 biopsy specimens from apparently healthy
blood donors infected with hepatitis C virus were
abnormal, with a third having evidence of chronic
active hepatitis or cirrhosis. Although peak alanine
aminotransferase concentration and biopsy scores
were strongly correlated, alanine aminotransferase
concentration was a poor predictor of serious liver
disease.
Possible explanations for the discordant results with
the test for hepatitis C virus RNA include intermittent
viraemia,5 low level viraemia, false positive or negative
results, and clearance of viraemia between sampling.
Larger studies are needed to determine whether
variable results for viral RNA are associated with less
severe liver disease.
We found no useful predictors of the severity of liver
disease. Our estimates of age at, and duration of,
infection, however, had obvious limitations. Our data
suggest that donors who have repeated positive results
for hepatitis C virus RNA require liver biopsy as a large
proportion will have serious liver disease that cannot
be predicted by measuring alanine aminotransferase
concentration.
Members of the Trent Regional Hepatitis C Virus Study
Group were D A Jones, P Nuttall (Trent Regional Blood
Transfusion Service); S Day (Nottingham University); D
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D R Triger, D Williams (Royal Hallamshire Hospital,
Sheffield); B B Scott (Lincoln County Hospital); K G
Nicholson, M Wiselka (Leicester Royal Infirmary); J
Freeman (Derby Royal Infinnary), and K Rose (Department
of Microbiology, University ofEdinburgh).
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Foliow up ofblood donors
positive for antibodies to
hepatitis C virus
Kate E Ryan, Sheila MacLennan, J A J Barbara,
Patricia E Hewitt
The hepatitis C virus has been identified as the main
cause of post-transfusion hepatitis.' Mandatory screen-
ing of blood donations for antibodies to hepatitis C
virus was introduced by the National Blood Trans-
fusion Service on 1 September 1991. Donors con-
firmed to be positive for antibodies to hepatitis C virus
at the North London Blood Transfusion Centre are
offered counselling by medical staff at the centre, who
explain the relevance of the test results. They are then
referred to their general practitioner.
Current evidence suggests that many of the
asymptomatic donors positive for antibodies to hepa-
titis C virus are chronic carriers, in whom the virus
replicates.2 Probably some asymptomatic donors will
progress to clinically significant, and possibly severe,
liver disease in the future. Follow up of the donor by
the general practitioner or hospital clinic, or both, will
be influenced by information and advice given as a
result of the initial counselling. To date there has been
Donors counselled at transfusion centre
70
Consulted general practitioner Failed to consult general practitioner
57 1 3
Consulted over Hepatitis C virus results not discussed
hepatitis C virus result by donor or general practitioner
54 3
Referred to specialist centre Not referred Unknown reasons
42 12 2
Abnormal Normal
liver function liver function l Normal
26 _ 6Unwilling liver function26 16
Seen by specialist Not yet seen
36 6
Liver biopsy Uver biopsy No
performed planned liver biopsy
6 525
Histological picture
* Mild inflammatory change 2 0 Chronic active hepatitis (mild) I
* Chronic persistent hepatitis I 0 Results not available 2
Flow chart showing management ofanti-HCVpositive blood donors
no information on the effectiveness of the counselling
procedure and the fate of donors after leaving the
transfusion centre. We carried out a postal survey on
the follow up arrangements for blood donors positive
for antibodies to hepatitis C virus.
Subjects, methods, and results
A postal questionnaire was sent to 83 of 107 blood
donors positive for antibodies to hepatitis C virus who
had been identified and counselled at the North
London Blood Transfusion Centre until the end ofJune
1992. The remaining donors were excluded either
because they had failed to attend for counselling (16
donors) or because they were uncontactable (eight
donors). A questionnaire was then sent to the doctors of
80 of these donors (two donors withheld consent and
in one case the general practitioner was unknown).
Replies were received from 50 donors and 61 general
practitioners (response rates 60% and 76% respec-
tively). Taken together, the questionnaire responses
gave information on 70 donors. Presentation of the
donor to the general practitioner and subsequent
management by the general practitioner are shown in
the flow chart. The demographic details and possible
sources of infection of these donors have been analysed
separately.3
Most ofthe donors positive for antibodies to hepatitis
C virus were referred for specialist opinion irrespective
of whether their liver function was reported as
abnormal by the transfusion centre. Of the 12 donors
not referred, four either refused or failed to attend
follow up appointments with the general practitioner
and six had normal liver function values; lack ofreferral
was in accordance with the centre's guidelines at the
time. Liver biopsy was performed or pending in 11
cases. One donor had been considered for treatment
with interferon alfa after the biopsy result.
The partners (all heterosexual) of 27 donors were
tested. None of 14 male partners and one of 13 female
partners was found to be infected, but details of
possible shared risk factors for this partner were not
available. Overall, general practitioners and donors
indicated satisfaction with the counselling service at
the transfusion centre. The main concems expressed
by donors were implications for sexual partners and for
future offspring.
Comment
The positivity rate positive for antibodies to hepatitis
C virus among first time donors at the North London
Blood Transfusion Centre is one in 1400. Based on
these figures, we should anticipate that 30 such
asymptomatic subjects would be identified annually at
the centre once the established donor panel had been
screened.
This survey shows that, after counselling, 13 of 70
donors did not consult their general practitioner about
their hepatitis C virus result. Of those who do,
however, most are being referred to a specialist clinic
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